Table 6.
GO and pathway enrichment analysis of the M. tuberculosis H37Rv genes that are predicted to target human TNF-alpha and IL-1~IL11 signaling pathways
TNF-Alpha | GO term ID | GO aspect | GO term name | % | Shared |
MTB genes that target human gene PSMC2 | GO:0005524 | F | ATP binding | 26.92 | Yes |
GO:0016020 | C | membrane | 20.51 | Yes | |
GO:0055114 | P | oxidation-reduction process | 16.67 | No | |
GO:0016310 | P | phosphorylation | 5.98 | No | |
GO:0006412 | P | translation | 5.13 | No | |
GO:0055085 | P | transmembrane transport | 2.14 | Yes | |
GO:0046933 | F | hydrogen ion transporting ATP synthase activity, rotational mechanism | 1.71 | No | |
Human gene PSMC2 | GO:0002479 | P | antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | – | – |
GO:0043687 | P | post-translational protein modification | – | – | |
GO:0045899 | P | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly | – | – | |
Targeted human genes | CASP10,BID,RUVBL2,DDX21,RPL4,BRINP1,PSMC2,PSMD1,FANCD2,MTIF2,PSMD2,PSMB5,RPS11,PSMC3,GLUL,PDCD2,KTN1 | ||||
IL-1 ~ IL-11 | GO term ID | GO aspect | GO term name | % | Shared |
M.TB genes that target the human gene VCP | GO:0003824 | F | catalytic activity | 32.17 | No |
GO:0016021 | C | integral to membrane | 16.78 | No | |
GO:0005524 | F | ATP binding | 27.27 | Yes | |
GO:0055114 | P | oxidation-reduction process | 9.79 | No | |
GO:0006810 | P | transport | 3.50 | Yes | |
GO:0006281 | P | DNA repair | 2.10 | No | |
Human gene VCP | GO:0005515 | F | protein binding | – | – |
GO:0006914 | P | autophagy | – | – | |
GO:0016236 | P | macroautophagy | – | – | |
GO:0010918 | P | positive regulation of mitochondrial membrane potential | – | – | |
GO:0006974 | P | cellular response to DNA damage stimulus | – | – |
Targeted human genes BCL2L11,UNC119,IRS1,IL2,DOK2,PTPN6,BAD,IL11,VCP,IRS2
C denotes cellular component, F denotes molecular function, and P denotes biological process